Why in news?
The Indian Council of Medical Research's antibiotic-resistance report for 2025 shows low susceptibility to several antibiotics in Klebsiella pneumoniae samples from participating hospitals. The bacterium can cause pneumonia, bloodstream infections and other serious infections. Resistance was particularly marked in samples from intensive care units. The findings make laboratory surveillance and infection prevention central to the response. They also help hospitals assess which antibiotics are likely to remain useful against the organisms found in their own patients.
The bacterium and the infections it causes
Klebsiella pneumoniae is a rod-shaped, Gram-negative bacterium. Gram-negative bacteria have a cell structure that includes an outer membrane. Klebsiella can normally occur in the human intestinal tract. It can also cause infection when it reaches other parts of the body or affects a vulnerable patient.
The US Centers for Disease Control and Prevention identifies risks in healthcare settings. Patients receiving care for other illnesses may need ventilators or intravenous catheters. Contaminated equipment and person-to-person contact can help bacteria spread. These routes make equipment care, hand hygiene and infection-control practices important parts of prevention.
What the ICMR network measures
The 2025 report covers a surveillance network of 30 tertiary-care hospitals and 34 secondary-care hospitals. Its reporting period is JanuaryโDecember 2025. Hospital laboratories identify organisms from clinical specimens and test them against antimicrobial medicines. An isolate is an organism recovered and grown from a sample for examination.
Antimicrobial susceptibility testing measures how the organism responds to a drug under standard laboratory conditions. The results help clinicians select treatment. An antibiogram brings together susceptibility results for an organism in a hospital or another defined setting. It can help guide an initial choice while a patient's own test results are awaited.
One ICMR table compares Klebsiella isolates from outpatient departments, wards and intensive care units. It includes clinical samples other than urine and faeces. Among ICU isolates tested against meropenem, 896 of 3,407 were susceptible, or 26.3%. Meropenem belongs to the carbapenem group of antibiotics used for some serious bacterial infections.
The percentage describes the tested isolates in that specified group. Clinical treatment also depends on the infection site, the patient's condition and the appropriate drug exposure. Results differ between hospitals and patient groups, so local laboratory information is valuable when treating an individual infection.
How resistance develops and spreads
Antimicrobial resistance develops when microbes acquire or retain features that let them survive a medicine's effects. Antibiotic use creates selection pressure. Susceptible bacteria are suppressed, while resistant bacteria can survive and multiply. Their resistance traits can then spread as the bacteria move between people or share genetic material.
Bacteria use several resistance mechanisms. Some produce enzymes that break down an antibiotic. Others change a drug's target, reduce its entry or pump it out. A resistant strain can therefore limit the medicines available for an infection. Unnecessary or inappropriate antibiotic use can accelerate this process.
Surveillance and prevention work together
Surveillance records which organisms are being found and how their drug responses change. Consistent laboratory methods allow comparisons across places and periods. Hospital infection-control teams can use those findings alongside information about patient locations, procedures and possible transmission.
Preventing infections reduces both illness and the need for antibiotics. The wider response includes clean water and sanitation, vaccination, reliable diagnostics and appropriate access to medicines. Antimicrobial stewardship supports appropriate antibiotic selection and use.
Conclusion
The ICMR findings support a response built around reliable testing, local treatment information and prevention of transmission. Hospitals need to track both resistant organisms and the conditions that allow infections to spread. That combination can improve antibiotic use while reducing avoidable infections.
Sources
- ICMR: AMR Surveillance Network annual report 2025, scope and Table 2.3
- The Indian Express: explanation of the ICMR report, 18 November 2026
- CDC: Klebsiella infections, risk factors and transmission
- CDC: resistance, selection pressure and mechanisms
- CDC NHSN: interpreting hospital antibiograms
- WHO: antimicrobial resistance and the public-health response
Lead illustration: Clarity ยท AI scientific illustration of representative Klebsiella bacteria.